01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
13:01 , Jun 25, 2019 |  BioCentury  |  Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

With $67 million in series A funding, newly launched Frontier Medicines Corp. believes that by using its massive database of protein binding hot spots and applying machine learning to its library of covalent compounds, the...
21:16 , May 6, 2019 |  BC Extra  |  Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
22:10 , Jan 25, 2019 |  BC Extra  |  Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....
22:11 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

M is for Chemoproteomic Momentum

An October Nature paper from a University of Cambridge team is the second in as many years to highlight the utility of functionalizing methionine, an amino acid that has garnered less attention than others in...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting MGLL could help treat chemotherapy-induced neuropathic pain. In a mouse model of paclitaxel-induced neuropathic pain, two tool compound MGLL inhibitors decreased mechanical allodynia compared with vehicle. Next steps could...
15:17 , Mar 30, 2018 |  BC Week In Review  |  Company News

Celgene licenses preclinical candidate from Abide

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
22:21 , Mar 28, 2018 |  BC Extra  |  Company News

Celgene, Abide reshuffle partnership

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...